Cancer Cell Behavior in Zero-G: How Microgravity Changes Tumor Growth

A cancer cell grown in a lab dish on Earth spreads out flat, like a pancake pinned to glass. The same cell, launched to the International Space Station, does something a Petri dish never lets it do: it floats free, bumps into its neighbors, and folds itself into a ball. That ball, called a spheroid, behaves far more like a real tumor than anything grown on a bench. Since the first orbital cancer cultures flew in the 2010s, researchers have used this quirk of physics to study drug resistance, gene activity, and tumor structure in ways that flat cultures simply cannot replicate.

The problem with growing cancer in a dish

Most of what scientists know about how cancer drugs kill cells comes from two-dimensional cultures — cancer cells grown as a single flat layer stuck to the bottom of a plastic dish. It is the cheapest, fastest, most standardized way to test a drug candidate, which is why it has dominated cancer labs for more than 50 years.

It is also a poor stand-in for an actual tumor. A real tumor is a three-dimensional mass with a blood supply that thins out toward the center, oxygen and nutrient levels that drop with depth, and cells that press against each other in every direction. A flat monolayer has none of that. Every cell in a 2D dish gets equal access to oxygen, glucose, and drug exposure, which is not what happens inside a person.

This mismatch has real consequences. Roughly 90% of oncology drug candidates that succeed in preclinical testing fail in human clinical trials, according to an analysis published in the British Journal of Cancer (Wong, Siah & Lo, 2019), and unrealistic lab models are widely cited as one contributing factor. If a drug only ever has to kill an evenly exposed flat layer of cells, it can pass early tests while failing against the uneven, oxygen-starved core of a real tumor.

Three-dimensional spheroid cultures — cells grown as free-floating balls rather than flat sheets — close part of that gap. They reproduce the nutrient gradients, cell-cell contacts, and structural stress of a real tumor mass far more closely than a monolayer does. The challenge on Earth is growing them consistently: gravity makes cells settle and clump unevenly, and most ground-based methods for making spheroids need mechanical stirring or scaffolding that can itself distort the biology researchers are trying to study.

An analysis in the *British Journal of Cancer* found that roughly 90% of oncology drugs that pass preclinical testing still fail in human trials — a gap researchers partly attribute to lab models, like flat 2D cell cultures, that behave nothing like real tumors.

Why weightlessness makes better tumor models

Microgravity solves the settling problem directly. Without gravity pulling cells to the bottom of a culture vessel, suspended cells stay evenly distributed and free to interact with each other from every direction, the way cells inside an actual tumor do. Left long enough, many cancer cell lines spontaneously aggregate into spheroids without any stirring, scaffolding, or mechanical intervention.

Think of it like the difference between letting flour settle in a still glass of water versus stirring it into a swirling vortex. On Earth, gravity is the "settling" force working against uniform 3D structure; only continuous artificial motion — spinning, rocking, or shaking — can counteract it, and that motion adds its own mechanical stress to the cells. In orbit, there is no settling force to fight, so the cells build their own three-dimensional architecture on their terms, driven by their own adhesion proteins rather than an external device.

This actually has a curious origin story back on Earth. In 1986, after the Challenger disaster grounded the Space Shuttle fleet, NASA engineer David Wolf needed a way to simulate microgravity's cell-culture effects without a rocket. He and colleagues Tinh Trinh and Ray Schwarz built a rotating cylindrical vessel — later called the Rotating Wall Vessel — that slowly tumbles a culture medium so cells experience a kind of continuous, gentle free fall (NASA Spinoff, 2009). It became the standard ground-based analog for microgravity cell culture and is still used today to make 3D tumor models for drug screening. Real spaceflight remains the gold standard, though, because true weightlessness removes gravitational settling entirely rather than just averaging it out through rotation.

What is a tumor spheroid?

A tumor spheroid is a solid ball of cancer cells grown without a flat surface to attach to, so it self-organizes in three dimensions the way a tumor mass does inside the body. Outer cells get plenty of oxygen and nutrients; inner cells face a low-oxygen, nutrient-poor core, closely mimicking the interior of a real tumor.

How do cancer cells actually form these structures in orbit?

Once suspended, cells reach out to each other using adhesion molecules — proteins on the cell surface, including cadherins and integrins, that let cells stick together and to a surrounding scaffold of proteins called the extracellular matrix. In microgravity, this adhesion machinery drives self-assembly into spheroids over the course of several days, according to a 2022 review in the International Journal of Molecular Sciences describing multicellular spheroids as a metastasis model (Ferranti et al., 2022).

Inside the missions: what has actually flown

Cancer research aboard the ISS is not a single ongoing experiment but a growing portfolio of discrete missions, each targeting a different cancer type and a different biological question. A few of the best-documented examples show how the field has progressed.

CellBox-1 and CellBox-2 (thyroid cancer). In one of the more thoroughly published cancer spaceflight studies, researchers sent FTC-133 human follicular thyroid cancer cells — derived from a lymph node metastasis in a 42-year-old patient — to the ISS aboard a SpaceX Falcon 9 launch on December 15, 2017. The cells were cultured in orbit at 28°C for 5 or 10 days before returning to Earth on January 12, 2018, as part of the CellBox-1 mission (Riwaldt et al., 2021, published in International Journal of Molecular Sciences).

The results were unexpected in one important way: rather than becoming more aggressive, the cells showed a broadly anti-proliferative response. Genes tied to cell adhesion and growth signaling — including VCL, PXN, ITGB1, and the NF-κB pathway components RELA, ERK1, and ERK2 — were significantly downregulated in the space-flown samples compared to Earth-based controls. The cells also spontaneously formed multicellular spheroids, and after ten days in orbit, secretion of a protein called angiopoietin-2, involved in blood vessel formation, rose sharply while most other measured proteins stayed flat, suggesting a selective rather than blanket cellular response to weightlessness.

The follow-up CellBox-2 mission, also 5 to 10 days on the ISS, extended the gene panel and found changes in extracellular matrix components (COL1A1, ITGB1), adhesion factors (CAV1, ICAM1, SRC, VCL, PXN), the growth factor receptor EGFR, and the inflammatory cytokines IL6 and CXCL8 (Corydon et al., cited in Stem Cells Translational Medicine review, 2025).

Breast cancer spheroids (MCF-7 and MDA-MB-231). These two widely studied breast cancer cell lines behave differently from each other in microgravity, which is itself informative. MCF-7 cells exposed to simulated and real microgravity for around 72 hours show disrupted actin and tubulin cytoskeletal networks, reduced levels of the focal adhesion protein vinculin, and increased apoptosis (programmed cell death) linked to weakened FAK-integrin signaling complexes.

MDA-MB-231 cells — a more aggressive, triple-negative breast cancer line — respond almost the opposite way over the same timeframe: upregulating AKT and KI67 (both linked to proliferation), CD44 (a marker of cancer stem cell-like behavior), and MMP9 (an enzyme tied to tissue invasion and metastasis), while also increasing the anti-apoptotic protein BCL2 and decreasing the pro-apoptotic protein BAX (Stem Cells Translational Medicine review, 2025). In other words, the same physical environment pushed one breast cancer line toward death and the other toward survival and invasion, depending on that line's underlying genetics.

Glioblastoma-immune organoids (SpX-30, 2024). A more recent mission, launched aboard the SpaceX SpX-30 commercial resupply flight in March 2024, sent microgravity-grown glioblastoma organoids paired with immune cells to the ISS specifically to study how brain tumors interact with the immune system in three dimensions — a step toward understanding why immunotherapy struggles against this notoriously treatment-resistant cancer (AACR Cancer Research abstract, 2025).

The results: an aggression-vulnerability paradox

Pulling these missions together, a consistent and somewhat counterintuitive pattern emerges: microgravity does not make cancer uniformly worse or uniformly weaker. It reshapes cell behavior in ways that depend heavily on cancer type, and it frequently produces both increased resistance and new points of vulnerability inside the same experiment.

Table: Documented cancer cell line responses to microgravity culture

Cancer type (cell line)	Culture duration	Key documented change	Source
Thyroid (FTC-133)	5–10 days, ISS (CellBox-1)	Spontaneous spheroid formation; downregulated adhesion/growth genes (VCL, PXN, ITGB1, ERK1/2); elevated angiopoietin-2	Riwaldt et al., Int. J. Mol. Sci., 2021
Breast, luminal (MCF-7)	~72 hours	Disrupted actin/tubulin cytoskeleton; reduced vinculin; increased apoptosis	Stem Cells Transl. Med. review, 2025
Breast, triple-negative (MDA-MB-231)	~72 hours to 14 days	Increased AKT, KI67, CD44, MMP9; increased BCL2, decreased BAX; more extracellular vesicle secretion at 5–10 days	Stem Cells Transl. Med. review, 2025
Lung (A549)	48–72 hours	Decreased proliferation; shift toward epithelial phenotype (increased E-cadherin); altered PIK3R1-Akt and PTEN signaling	Stem Cells Transl. Med. review, 2025
Gastric (EPG85-257)	24–96 hours	Changed multidrug-resistance gene expression; increased chemotherapy susceptibility	Stem Cells Transl. Med. review, 2025
Pancreatic (PaCa-44)	1–9 days	Enhanced stem cell-like, invasive, epithelial-to-mesenchymal phenotype	Masini et al., cited in Stem Cells Transl. Med. review, 2025

Caption: Cell-line-specific responses to microgravity culture, compiled from peer-reviewed studies using real (ISS) or simulated ground-based microgravity platforms.

Three findings from this body of work carry the most weight for cancer therapy research.

Structure changes drug response. Spheroid cores are harder for drugs to penetrate and often contain slower-dividing cells, since many chemotherapy drugs specifically target rapidly dividing cells. That alone can make a spheroid model more drug-resistant overall than the same cells grown flat — which sounds like bad news, except that this resistance mirrors what oncologists actually see in patients, making spheroid drug screening a better predictor of real-world response than 2D screening ever was.

Some drugs work better against spheroids, not worse. Counterintuitively, the gastric cancer line EPG85-257 became more susceptible to certain chemotherapy agents in rotating-wall-vessel culture even as its multidrug-resistance gene expression shifted, according to the same review. This kind of result — a drug performing better against a 3D structure than a flat one — cannot be discovered in monolayer culture at all, because monolayer culture has no structure to test against.

Cancer type dictates the direction of change. The same physical stimulus pushed thyroid cancer cells toward reduced growth signaling, one breast cancer line toward death, a different breast cancer line toward invasion markers, and a pancreatic cancer line toward a more stem-like, aggressive state. This is the single most consequential finding across the field: microgravity is not a "cancer accelerant" or a "cancer suppressant" as a category. It is a structural and mechanical stress test, and different cancers pass or fail that test in genetically determined, cell-line-specific ways.

The most striking result is not that microgravity makes cancer more dangerous. It is that the identical physical environment sends different cancer types in opposite directions — some toward death, others toward invasion — a divergence flat 2D cultures cannot even reveal, let alone explain.

Why this matters beyond the space station

The practical payoff of this research is not "cancer treatment in orbit." It is better cancer models on Earth, built using knowledge orbital experiments reveal.

Predictive drug screening. Because spheroid-based gene expression patterns more closely resemble patient tumor biopsies than 2D culture data does, pharmaceutical researchers are using microgravity-derived spheroid data to flag drug candidates likely to underperform in clinical trials before those trials ever begin, potentially reducing the roughly 90% late-stage failure rate cited above.

Better ground-based 3D models. Every gene pathway identified as microgravity-responsive — NF-κB and ERK signaling in thyroid cancer, FAK-integrin signaling in breast cancer, PIK3R1-Akt in lung cancer — becomes a target that ground-based labs can specifically probe using Rotating Wall Vessel bioreactors and other Earth-based 3D culture systems, without needing a spaceflight slot for every experiment.

Metastasis modeling. Because forming a spheroid requires cells to detach, float free, and re-aggregate, the process itself mirrors early steps of metastasis — the process by which cancer cells break away from a primary tumor and establish new growths elsewhere in the body. Studying that detachment-and-reaggregation sequence under microgravity gives researchers a live model of a process that is otherwise difficult to observe directly in patients.

Immunotherapy development. The 2024 glioblastoma-immune organoid mission points toward a broader use of orbital 3D culture: pairing tumor models with immune cells to study why some cancers, particularly brain tumors, resist immunotherapy far more than others. Findings from that line of research are still preclinical, but the organoid-plus-immune-cell approach is a direct extension of the spheroid work described above.

What people get wrong about this research

Myth: astronauts are being treated for cancer in orbit. No patient has ever been treated for cancer aboard the ISS. Every cancer cell sample flown to orbit is a laboratory research tool — cultured cell lines or, in newer experiments, patient-derived organoids used purely for study. None of it involves treating an actual person in space.

Myth: space-grown cancer cells are more dangerous or contagious. Cells cultured in microgravity are genetically identical to their ground counterparts; only their growth environment differs. A spheroid returned from the ISS poses no different biosafety risk than the same cell line grown in a standard biosafety cabinet on Earth, and all such samples are handled under the same laboratory containment protocols used for any cultured human cancer cell line.

Myth: microgravity always makes cancer more aggressive. As the table above shows, this is the opposite of what the data actually says as a blanket rule. Some lines become more invasive; others become more apoptotic and easier to kill. The honest summary is "context-dependent," not "worse."

Myth: this research will lead to a single breakthrough cancer cure. The value of orbital cancer research is incremental and mechanistic — better models, better-validated drug targets, and a clearer picture of which signaling pathways matter for which cancer types. It functions as an upstream input into the normal, multi-year drug development pipeline, not as a shortcut around it.

Myth: any lab can just replicate these results with a lab centrifuge. Ground-based analogs like the Rotating Wall Vessel approximate several effects of microgravity reasonably well, but reviews directly comparing real ISS-flown samples to simulated-microgravity ground controls have found both similarities and meaningful differences in cell signaling outcomes, meaning true spaceflight data cannot be fully substituted by ground simulation alone.

The takeaway

Cancer cells grown weightless do not become one thing — more dangerous or more fragile — they become more honest, mechanically freed from the artificial flatness that has shaped cancer biology data for half a century. That honesty produces a split result: some cancer types drift toward invasion and stemness, others toward structural collapse and death, and the deciding factor is the cell's own genetics reacting to a truly three-dimensional, unconstrained environment. The lasting contribution of ISS cancer research will not be a treatment developed in orbit. It will be a permanent upgrade to how drugs are tested on the ground, using gene targets and spheroid models that a flat Petri dish could never have surfaced.

FAQ

Q: Can cancer cells from ISS culture directly treat patients? A: No. Cells grown in orbit are research tools used to study tumor biology and drug response, not therapies themselves. Insights from these experiments feed into standard preclinical and clinical drug development on Earth, a process that typically takes years.

Q: Are space-grown cancer cells more dangerous than terrestrial ones? A: No. The cells are genetically identical to ground-cultured versions of the same line; only the growth environment differs. They are handled under the same laboratory biosafety protocols as any other cultured human cancer cell line.

Q: Does microgravity make cancer cells grow faster? A: It depends on the cancer type. Documented studies show some lines, like certain breast and pancreatic cancer cells, increasing markers linked to proliferation and invasion, while others, like thyroid and lung cancer cells, show reduced growth signaling and increased apoptosis under the same conditions.

Q: Why do cancer cells form spheroids in microgravity without any special equipment? A: Without gravity pulling cells to the bottom of a culture vessel, suspended cells remain in contact with each other from every direction. Adhesion proteins called cadherins and integrins then drive the cells to self-assemble into a 3D ball over several days.

Q: Do drug screening results from spheroid models match clinical outcomes better than flat 2D cultures? A: Evidence suggests they do. Because spheroids reproduce the oxygen gradients, structural stress, and cell-cell contact of real tumors, gene expression patterns in spheroid models resemble patient tumor samples more closely than 2D monolayer cultures do.

Q: What is the Rotating Wall Vessel and how does it relate to ISS cancer research? A: It is a NASA-developed bioreactor, invented in 1986 by David Wolf and colleagues after the Challenger disaster grounded the Space Shuttle fleet, that rotates a culture medium to approximate microgravity's effects on cell growth. It remains the standard ground-based method for making 3D tumor models when spaceflight is not available.

Q: Are there cancer types where microgravity particularly changes cell behavior? A: Yes. Documented studies show clear differences even between subtypes of the same cancer — for example, two breast cancer lines, MCF-7 and MDA-MB-231, responded in nearly opposite directions to similar microgravity exposure, one trending toward cell death and the other toward invasion markers.

Q: Has microgravity cancer research led to any cancer drugs currently used in patients? A: No drug currently in clinical use originated from ISS cancer experiments. The research is upstream of drug development, providing gene targets and improved preclinical models rather than finished therapies. Translating a target identified in orbit into an approved drug follows the same multi-year regulatory pipeline as any other discovery.

Q: How is this different from the "protein crystals in space" research also done on the ISS? A: Protein crystal growth experiments study the physical structure of individual proteins to help design new drugs, while cancer cell experiments study how whole living cells and tumor-like structures behave and respond to treatment. They use the same microgravity environment for different purposes within drug discovery.

Q: Could future research use a patient's own tumor cells in microgravity experiments? A: This is an active research direction. Some newer missions, including a 2024 ISS experiment pairing glioblastoma organoids with immune cells, point toward using patient-derived tumor material in orbital 3D culture to study individualized treatment response, though this remains preclinical work rather than a clinical service.

---

Read next:

• Genetic Expression in Microgravity: What Space Reveals About Our DNA
• Protein Crystal Growth in Microgravity: Solving Disease at 400km Altitude
• The CRISPR Gene Editing Breakthrough
• Why Naked Mole Rats Resist Cancer

---

Sources:

• Wong, Siah & Lo, "Estimation of clinical trial success rates and related parameters," British Journal of Cancer (2019) — nature.com
• Riwaldt et al., "The Fight against Cancer by Microgravity: The Multicellular Spheroid as a Metastasis Model," International Journal of Molecular Sciences (2022) — PMC8953941
• "The CellBox-2 Mission to the International Space Station: Thyroid Cancer Cells in Space," International Journal of Molecular Sciences — PMC8395939
• "Recent studies of the effects of microgravity on cancer cells and the development of 3D multicellular cancer spheroids," Stem Cells Translational Medicine (2025) — PMC11914975 / Oxford Academic
• "Leveraging the International Space Station to study glioblastoma-immune interactions in microgravity-grown organoids," Cancer Research, AACR Abstract 5190 (2025) — aacrjournals.org
• "NASA Bioreactors Advance Disease Treatments," NASA Spinoff (2009) — spinoff.nasa.gov